Dr John O'Sullivan

Heart Research Institute
Charles Perkins Centre

Member of the Charles Perkins Centre


Map

Biographical details

Dr John O’Sullivan is a cardiologist and scientist who studies cardiometabolic disease, particularly the nexus of obesity, diabetes, and cardiovascular disease, now based at the Royal Prince Alfred Hospital, the HRI, and the Charles Perkins Centre. He completed his medical and cardiology training in Ireland, and spent the last 4 years on a postdoctoral fellowship at the Gerszten Lab at Massachusetts General Hospital, Harvard Medical School, and the Broad Institute of Harvard and MIT. There, he performed large scale targeted and non-targeted metabolomics profiling on subjects in the Framingham Heart Study (FHS), validating findings in unrelated cohorts such as the Malmö Diet and Cancer Study (MDC), the Diabetes Prevention Program, and the Jackson Heart Study. This work led to the identification of a number of novel markers and effectors of cardiometabolic disease. Subsequent work demonstrated the ability of intracellular metabolomics profiling to replicate “human disease in a dish” using iPS cells from FHS patients with specific genetic variants. More recently, John performed GWAS on non-targeted metabolomics data to identify an unknown metabolite associated with CT-defined liver fat, subsequently validated this finding in a biopsy-proven cohort, and then demonstrated the ability of this metabolite to predict future diabetes 12 years ahead of presentation in three cohorts of different ethnicity. John’s work has been recognized by a number of Young Investigator Awards at the American College of Cardiology, American Heart Association (AHA) (x2), and Irish Cardiac Society; Fellowship of the AHA; a Harvard Medical School Tosteson Award; the NSW Ministerial Award for Rising Starts in Cardiovascular Research 2016; in addition to other awards at the European Society of Cardiology, Massachusetts General Hospital, and the Irish Cardiac Society. He is keen to expand on this work here in Australia by fostering meaningful and long-lasting collaborations.

Research interests

Research Project Opportunities

Uncovering Novel Cardiovascular Disease Pathways

We are utilising robustly-phenotyped patient cohorts in concert with genomic, transcriptomic, and metabolomic profiling to shed new light on gene-environment interaction in cardiovascular disease. In addition to providing new markers and predictors of disease, this approach can uncover new targets for therapy. Furthermore, it is becoming increasingly evident that a ‘one-size-fits-all’ approach to cardiovascular prevention and treatment is sub-optimal. We believe re-stratifying risk and targeting disease based on a patient’s unique profile is a far more effective strategy. We have previously identified novel markers and predictors of cardiometabolic disease, in addition to a new disease pathway linking fatty liver disease with diabetes.

Probing a New Metabolic Disease Pathway

While working with Professor Robert Gerszten at Harvard Medical School, we recently discovered a new pathway linking fatty liver disease and diabetes. Integrating non-targeted metabolomic profiling (which captures thousands of metabolites) with genome-wide association (GWAS), we elucidated the chemical identity of a new marker of fatty liver disease. After synthesis and purification, we developed a new assay that we used to show this same marker independently predicted diabetes over a decade in advance in the Malmo Diet and Cancer Study (a Caucasian cohort) and the Jackson Heart Study (an African-American cohort). We are now focusing on functionally interrogating this pathway in model systems, including genetically-modified mouse models.

Discovery Profiling

Truly novel small molecule biomarker discovery is very challenging, and non-targeted metabolomic profiling offers this potential. However, success stories using this approach are extremely rare. We have previously identified novel disease metabolites using this approach, both in a clinical cohort and in a cell-model system. We are extending our capability and streamlining our discovery pipeline. We have unique expertise with the latest-generation mass spectrometers, chemometric software, and integrative ‘omics’. Furthermore, we are recruiting bioinformaticians to develop novel algorithm, machine learning, and network analysis approaches that harness vast open-access online databases to inform our own data.

Current projects

1. Novel Pathways in Ischaemic Heart Disease

There are now >70 genetic loci associated with coronary artery disease (CAD), and surprisingly over two-thirds of these are not associated with traditional CAD risk factors. Contribution of genetic variation to disease is complex, particularly for diseases such as CAD that develop over the lifetime of an individual. This may partially explain the apparent lack of association of these loci with CAD risk factors. Understanding the mechanisms involved are important, especially for high-risk groups, e.g. family members of individuals having an unexplained heart attack at a young age - we are uncovering how these gene loci confer risk. By integrating genomic and metabolomic data in >1,000 patients in the Framingham Heart Study (FHS), we previously investigated how CAD gene loci acting through unknown mechanisms confer their risk. For example, we discovered that the CAD gene ZC3HC1 is in fact associated with many lipid species, likely conferring its risk for CAD through this intermediate phenotype. We are extending our exploration of CAD pathways using cryopreserved human myocardium from the Sydney Heart Bank via collaboration with Dr Sean Lal from the School of Medical Sciences at the University of Sydney. Excitingly, we have replicated findings made in our initial investigations in the FHS, and are now focussing on three novel pathways active in ischaemic heart disease. We will explore the underlying mechanisms in cellular and animal model systems to determine if these are viable therapeutic targets.

Team members working on this project:

· Dr Jacob Cao, Medical Resident, Postdoctoral Scientist

2. A Key Metabolic Switch in Cardiometabolic Disease

Non-alcoholic fatty liver disease (NAFLD) is now the commonest form of liver disease in the Western world, affecting one in three people in the general population, 90% of obese patients with T2D, and 5.5 of 6 million Australians with liver disease – accounting for much of the $51 billion annual cost to our healthcare system. Liver fat is increasingly considered a primary driver of T2D, although exact mechanisms remain unclear, and is an independent risk factor for atherosclerosis. Further - and most clinically challenging - it is unknown which patients with liver fat will progress to metabolic complications.

We recently discovered a new plasma biomarker (dimethylguanidino valeric acid [DMGV]) of liver fat that independently predicted diabetes up to 12.8 years before diagnosis in three distinct human cohorts of different ethnicity (O’Sullivan et al., J Clin Invest, 2017). We have subsequently shown that DMGV is elevated in a human cohort of hepatic insulin resistance, and that the gene producing DMGV is upregulated in fatty liver disease. Intriguingly, in dietary models of NAFLD, we found sucrose (fructose + glucose) caused the most dramatic dysregulation of this pathway, consistent with recent reports showing fructose to have dramatic effects on hepatic insulin resistance in humans and mice. Together, these data suggest this pathway is most activated in lipogenesis leading to hepatic insulin resistance. We have put together a comprehensive plan to test our proposed hypothesis, including dietary models and genetically modified murine models in addition to liver biopsy and plasma samples from carefully characterized human cohorts.

Reference:

DMGV is a Marker of Liver Fat and Predicts Future Diabetes.

John F O’Sullivan, Jordan E Morningstar, Baohui Zheng, Sarah Jeanfavre, Justin Scot, Qiong Yang, Celine Fernandez, Ramachandran S. Vasan, Michelle T. Long, Olle Melander, Thomas J. Wang, Caroline Fox, Randall T. Peterson, Clary Clish, Kathleen Corey, Robert E. Gerszten.

J Clin Invest. 2017. PMID: 29083323.

Team members working on this project:

· Dr Yen Chin Koay, Postdoctoral Scientist, Synthetic Chemist

3. Targeted Therapy in Type 2 Diabetes.

Together with our collaborator Dr Dorit Samocha-Bonet of the Garvan Institute in Sydney, we are investigating strategies for targeted therapeutic approaches to Type 2 Diabetes. The current paradigm is one of trial-and-error, in which metformin therapy is first-line. However, 20-50% of patients do not respond to metformin, after which other agents are tried in a step-wise fashion. In a cohort of patients carefully phenotyped for hepatic or skeletal muscle insulin resistance by hyperinsulinaemic-euglycaemic clamp, we have discovered a new plasma biomarker of hepatic insulin resistance. While this biomarker is undergoing further validation, it will be developed to guide therapy in the clinic, e.g. high levels mean patients would likely benefit from metformin; a low level would suggest patients should bypass metformin. This guided therapeutic approach could avoid unwarranted therapies and unwanted side-effects, and ultimately accelerate the path to effective treatment.

In addition to this exciting discovery, we are developing a “multi-marker” using a machine-learning approach. This multi-variable score will incorporate metabolites, lipid species, chemical pathology, and clinical parameters and we anticipate will be far more powerful than a single biomarker in the guidance of targeted therapy.

Team members working on this project:

· Dr Yen Chin Koay, Postdoctoral Scientist, Synthetic Chemist

Awards and honours

Select Awards:

1stPlace, Young Investigator Award, American College of Cardiology (2011).

1stPlace, Young Investigator Award, Irish Cardiac Society (2011).

Young Investigator Award, American Heart Association (Melvin Judkins Award) (2011).

Fellowship of the American Heart Association (FAHA) (2011).

“Top 30 Outstanding Young People in the World” (Medical Innovation), JCI (2011).

Prof Raymond Shanahan Prize in Cardiovascular Research, University College Cork, Cork, Ireland (2011).

Prof Brian McGovern Overseas Training Fellowship to Massachusetts General Hospital; Cardiac Society (2011).

1stPlace Poster, MGH CVRC at the American Academy of Sciences (2014).

Harvard Medical School Tosteson Award for Medical Discovery (2014).

Poster of Distinction Award, 67thAnnual Massachusetts General Hospital Scientific Advisory Committee Meeting (2014).

Young Investigator Award, American Heart Association (AHA) Functional Genomics and Translational Biology (2016).

NSW Ministerial Award for Rising Stars in Cardiovascular Research Excellence (2016).

Sydney Medical School Foundation Chapman Fellowship (2017).

In the media

Publications:

Original Research Articles:

  • DMGV is a marker of liver fat and predicts diabetes.John F O’Sullivan,Jordan E Morningstar, Baohui Zheng, Sarah Jeanfavre, Justin Scot, Qiong Yang, Celine Fernandez, Ramachandran S. Vasan, Michelle T. Long, Olle Melander, Thomas J. Wang, Caroline Fox, Randall T. Peterson, Clary Clish, Kathleen Corey, Robert E. Gerszten.

J Clin Invest. 2017. PMID: 29083323.

  • Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. Stephen T Vernon, Sean Coffey, Ravinay Bhindi, Soon Yeng Soo Hoo, Gregory I Nelson, Michael R Ward, Peter S Hansen, Kaleab N Asrress, Clara K Chow, David Celermajer,John F. O’Sullivan, and Gemma A Figtree.

European Journal of Preventive Cardiology.2017 Jan 1:2047487317720287. PMID:28703626 .

  • Induced Pluripotent Stem Cell Differentiation Enables Functional Validation of GWAS Variants in Metabolic Disease. Curtis R. Warren,John F. O’Sullivan, Max Friesen, Caroline E. Becker, Xiaoling Zhang, Yoshi Wakabayashi, Jordan E. Morningstar,Xu Shi, Jihoon Choi, Fang Xia, Mary H. C. Florido, Jennifer Shay, Derek T. Peters, Kiran Musunuru, Sekar Kathiresan, Laurence Daheron, Jun Zhu, Robert E. Gerszten, Rahul Deo, Vasan Ramachandran, Christopher J. O’Donnell, and Chad A. Cowan.

Cell Stem Cell.2017 Apr 6;20(4):547-557. (Impact Factor 23.6). PMID: 28388431.

  • Metabolomic Profiling Identifies Anandamide as a Biomarker of nonalcoholic steatohepatitis. William.T. Kimberly,John F O’Sullivan, Anjali Nath, Michelle Keyes, Qiong Yang, Martin G. Larson, Vasan Ramachandran, Randall T. Peterson, Thomas J. Wang, Kathleen Corey, and Robert E. Gerszten.

J Clin Invest. Insight.2017 May 4;2(9). PMID: 28469090.

  • HELZ2 is an IFN Effector Mediating Suppression of Dengue Virus. Dahlene Fusco, Henry Pratt, Wenyu Lin, D. Alex Cronkite, Kate Jeffrey, Joshua Pondick, Alan Mullen, Anthony Anselmo, Ruslan Sadreyev,John O’Sullivan, Robert Gerszten, Tetsurou Satoh, Raymond T. Chung.

Frontiers in Microbiology.Front Microbiol. 2017 Feb 20;8:240. PMID: 28265266.

  • Aptamer-based proteomic profiling reveals novel candidate biomarkers of cardiovascular disease. Debby Ngo, Sumita Sinha, Dongxiao Shen, Eric Kuhn, Michelle Keyes, Xu Shi, Mark Benson,John F O’ Sullivan, HasmikKeshishian, Laurie Farrell, Michael A. Fifer, Ramachandran S. Vasan, Marc Sabatine, Martin G. Larson, Steven A. Carr, Thomas J. Wang, Robert E. Gerszten.

Circulation.2016; 134:270-285. (Impact Factor 14.4). PMID: 27444932.

  • miR-93-5p and other miRNAs as Predictors of Stable Coronary Artery Disease and STEMI.JF O’Sullivan, A Neylon, C McGorrian, G Blake.

International Journal of Cardiology.Dec 2016, Vol 24, 310-316. (Impact Factor 4.0). PMID: 27665403.

  • Integrative analysis of iPS cell models of PRKAG2 cardiomyopathy identifies AMPK as a regulator of cardiomyocyte survival, contractility and fibrosis in microtissues. J. Travis Hinson, Anant Chopra, Calvin C. Sheng, Rajat M. Gupta, Rajarajan Kuppusamy,John F.O’Sullivan, Glenn Rowe, Joshua Gorham, Kiran Musunuru, Robert E. Gerszten, Sean M. Wu, Christopher Chen, Jonathan E. Seidman, Christine E. Seidman.

Cell Reports.2016 Dec 20;17(12):3292-3304.PMID: 28009297. (Impact Factor 7.9).

  • Rapid and efficient generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Christoph Patsch, Ludivine Challet-Meylan, Eva Christina Thoma, Eduard Urich, Tobias Heckel,John F O’Sullivan, Stephanie J Grainger, Friedrich G Karpp, Lin Sun, Klaus Christensen, Yulei Xia, Marie Florido, Wei He, Wei Pan, Michael Prummer, Curtis Warren, Oliver Wernet, Roland Jakob-Roetne, Ulrich Certa, Ravi Jagasia, Per-Ola Freskgård, Isaac Adatto, Dorothee Kling, Paul Huang, Leonard I Zon, Elliot Chaikof, Robert E. Gerzsten, Martin Graf, Roberto Iacone and Chad A. Cowan.

Nature Cell Biology.2015 Aug;17(8):994-1003. (Impact Factor 18.7). PMID: 26214132.

PLoS One.2014 Jun 16;9(6):99058. (Impact Factor 3.2).PMID: 24932507.

  • β-Aminoisobutyric Acid Increases Browning of White Fat and Hepatic β-Oxidation and is Inversely Correlated with Cardiometabolic Risk Factors in Humans. Lee D. Roberts, Pontus Boström,John F. O'Sullivan, Robert T. Schinzel, Gregory D. Lewis, Youn-Kyoung Lee, Melinda J. Palma, Sondra Calhoun, Ming-Huei Chen, Vasan S. Ramachandran, Martin G. Larson, Claude Bouchard, Tuomo Rankinen, Amanda L. Souza, Clary B. Clish, Thomas J. Wang, Alexander A. Soukas, Chad A. Cowan, Bruce M. Spiegelman, Robert E. Gerszten.

Cell Metabolism.Volume 19, Issue 1, 96-108, 7 January 2014. (Impact Factor 17.6).PMID: 24411942.

  • Bone marrow-derived mesenchymal stem cells have innate procoagulant activity and cause microvascular obstruction following intracoronary delivery: amelioration by anti-thrombin therapy. Birgitta M Gleeson,Kenneth Martin, Arun HS Kumar DVM, Mohammed T Ali, M Gopala-Krishnan Pillai,John F O’Sullivan, Derek Whelan, Frank P Barry, Timothy O’Brien, Noel M Caplice.

Stem Cells.2015 Sep;33(9):2726-37.(Impact Factor 7.8). PMID: 25969127.

  • 2-aminoadipic acid is a novel biomarker of diabetes risk and modulates glucose homeostasis. Wang TJ, Ngo D, Psychogios N, Dejam A, Larson MG, Vasan RS, Ghorbani A,O'Sullivan J, Cheng S, Rhee EP, Sinha S, McCabe E, Fox CS, O'Donnell CJ, Ho JE, Florez JC, Magnusson M, Pierce KA, Souza AL, Yu Y, Carter C, Light PE, Melander O, Clish CB, Gerszten RE.

J Clin Invest. 2013 Oct 1;123(10):4309-4317. (Impact Factor 12.6). PMID: 24091325..

  • Multi Detector Computed Tomography Accurately Defines Infarct Size, but not Microvascular Obstruction After Myocardial Infarction (MI).John F O’Sullivan, MD, PhD, Anne-Laure Leblond, PhD, John O’Dea, MD, Ivalina Hristova, BS, Sujith Kumar, DMRIT, Noel M Caplice, MD, PhD.

J Am Coll Cardiol. 2013;61(2):208-210. (Impact Factor 17.8). PMID: 23177294.

  • Association of Bicuspid Aortic Valve with an Abnormally Elongated Rudimentary Chordae Tendinae Protruding into the Left Ventricular Outflow Tract. Abid Hussaini,John F O’Sullivan, Nazima Hussaini, Brendan Meany

Int J Cardiol.01/2012; 159(3):45-6. (Impact Factor 4.0). PMID: 22217483.

  • Potent Long-term Cardioprotective Effects of Single Low Dose Insulin-like Growth Factor-1 (LD-IGF-1) Treatment Post Myocardial Infarction.John F O’Sullivan, Anne-Laure Leblond, Geraldine Kelly, Arun HS Kumar, Pat Metharom, Ivalina Hristova, Niki Alizadeh-Vikali, Brian G Hynes, Rosemary O’Connor, Noel M Caplice.

Circulation: Cardiovascular Interventions2011;4:327-335. (Impact Factor 7.0). PMID: 21712526.

  • Potent EPC conditioned media induced anti-apoptotic, cardiotrophic and proangiogenic effects post myocardial infarction are mediated by IGF-1. Brian Hynes, Arun HS Kumar,John O’Sullivan, Anne-Laure Leblond, Sharon Weiss, Jeffrey Schmeckpeper, Kenneth Martin, Noel M Caplice.

Eur Heart J.2011 Dec 15. (Impact Factor 15.2). PMID: 22173909.

  • Thrombin Stimulates Smooth Muscle Cell Differentiation From Peripheral Blood Mononuclear Cells via Protease-Activated Receptor-1, RhoA, and Myocardin. Kenneth Martin, Sharon Weiss, Pat Metharom, Jeffrey S Schmeckpeper, Brian G Hynes,John F O’Sullivan, Noel M Caplice.

Circulation Research.2009;105:214-218. (Impact Factor 11.0). PMID: 19574550.

  • Enhancing Back-up Support During Difficult Coronary Stent Delivery: Single Center Case Series of Experience with the Heartrail II Catheter. Brian Hynes, Grainne Murphy, James Dollard,John O’Sullivan, Nicholas Ruggerio, Ronan Margey, Thomas J. Kiernan, Eugene McFadden

J Invasive Cardiol.2011;23(3):E43-6. (Impact Factor 1.1).PMID: 21364247.

  • Bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction. Anne-Laure Leblond,John O’Sullivan, Noel Caplice.

Stem Cells and Cloning: Advances and Applications.December 2009, Volume 2009:2 Pages 11 – 19. (Impact Factor 2.7). PMID: 24198506.

  • Ostial left main stenosis in a frequent flyer.O’Sullivan JF, McFadden E

Int J Cardiol.2008 Mar 28.(Impact Factor 4.0). PMID: 18378023.

  • Soft tissue neoplasm invading the heart with associated thrombus in a 74 year old man.John O'Sullivan, David Kerins, Peter McEneaney, Carl Vaughan

Eur J Echocardiogr. 2007 Jul 30. (Impact Factor 4.3).PMID: 17669689.

  • Massive thrombus in the aortic arch: A 59-year-old lady with an unknown familial predisposition to vascular thrombosis.O’Sullivan J, Kerins D, Vaughan C.

Eur J Echocardiogr. 2007 Sep 19. (Impact Factor 4.3). PMID: 17888744.

  • Distinct Effects of High-Glucose Conditions on Endothelial Cells of Macrovascular and Microvascular Origins. A. Duffy, A. Liew,J. O’Sullivan, G. Avalos, A. Samali, T. O’ Brien.

Endothelium.2006 Jan-Feb;13(1):9-16. (Impact Factor 5.5). PMID: 16885062

  • Survival of ruptured abdominal aortic aneurysms in the west of Ireland; do prognostic indicators of outcome exist? Sultan S, Maneshka R,O’ Sullivan J, Hynes N, Quill D, Courtney D.

Vasc Endovasc Surg.2004, Jan-Feb; 38(1):43-9. (Impact Factor 0.9). PMID: 14760476.

  • Aortic Surgery: Do preoperative Cardio-selective β-blockers improve clinical outcome? Sultan S,O’Sullivan J, Manecksha R, Ishak L, Sharman A, Quill D, Courtney D

Irish Journal of Medical Science.01/2002; 171(3):S2:20. (Impact Factor 1.12).

  • Ruptured abdominal aortic aneurysms: prognostic indicators for outcome. Sultan S, Manecksha R,O’Sullivan J, Ishak L, Sharman A, Quill D, Courtney D

Irish Journal of Medical Science.01/2002; 171(3):S2:22. (Impact Factor 1.12).

Reviews:

  • Microribonucleic acids for Prevention of Plaque Rupture and Instent Restenosis: “A Finger in the Dam”.John F O’Sullivan, Kenneth Martin, Noel M Caplice.

State of the Art Paper.J Am Coll Cardiol.2011 Jan 25;57(4):383-9. (Impact Factor 17.8). PMID: 21251577.

  • New Therapeutic Potential of MicroRNA Treatment to Target Vulnerable Atherosclerotic Lesions and Plaque Rupture. Kenneth Martin,John F O’Sullivan, Noel M Caplice.

Current Opinion in Cardiology.2011 Sep 13. (Impact Factor 2.7).PMID: 21918434.

  • MicroRNA Expression in Coronary Artery Disease.John F O’Sullivan, Antoinette Neylon, Catherine McGorrian, Gavin J Blake

MicroRNA.Volume 2, Issue 3, 2013. (Impact Factor 3.8). PMID: 25069444.

Invited Reviews:

  • Metabolite Profiles and the Risk of Cardiometabolic Disease.O’Sullivan J, Gerszten RE

Eur Heart J.2014; 35; 2197–2204. (Impact Factor 15.2). DOI: 10.1093/eurheartj/ehu270.

Research – Book chapters

  • O’Sullivan, J.F., Leblond, A-L, and Caplice, N.M. (2011) Chapter 12 A key role of angiogenesis in recovery from ischaemic heart disease. In M.A. Slevin (ed.)Therapeutic Angiogenesis for Vascular Diseases.Elsevier. pp 267-294. DOI: 10.1007/978-90-481-9495-7_12.

Selected grants

2017

  • SMS Foundation Grant; O'Sullivan J; Sydney Medical School Foundation/Foundation Grant.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • O'Sullivan, J., Morningstar, J., Yang, Q., Zheng, B., Gao, Y., Jeanfavre, S., Scott, J., Fernandez, C., Zheng, H., O'Connor, S., et al (2017). Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. Journal of Clinical Investigation, 127(12), 4394-4402. [More Information]
  • Fusco, D., Pratt, H., Kandilas, S., Cheon, S., Lin, W., Cronkite, D., Basavappa, M., Jeffrey, K., Anselmo, A., O'Sullivan, J., et al (2017). HELZ2 Is an IFN Effector Mediating Suppression of Dengue Virus. Frontiers in Microbiology, 8, 1-20. [More Information]
  • Vernon, S., Coffey, S., Bhindi, R., Hoo, S., Nelson, G., Ward, M., Hansen, P., Asrress, K., Chow, C., Celermajer, D., O'Sullivan, J., Figtree, G. (2017). Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. European Journal of Preventive Cardiology, 24(17), 1824-1830. [More Information]
  • Warren, C., O'Sullivan, J., Friesen, M., Becker, C., Zhang, X., Liu, P., Wakabayashi, Y., Morningstar, J., Shi, X., Choi, J., et al (2017). Induced Pluripotent Stem Cell Differentiation Enables Functional Validation of GWAS Variants in Metabolic Disease. Cell Stem Cell, 20(4), 547-5.57. [More Information]
  • Kimberly, W., O'Sullivan, J., Nath, A., Keyes, M., Shi, X., Larson, M., Yang, Q., Long, M., Vasana, R., Peterson, R., et al (2017). Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis. JCI Insight, 2(9), 1-9. [More Information]
  • Ngo, D., Sinha, S., Shen, D., Kuhn, E., Keyes, M., Shi, X., Benson, M., O'Sullivan, J., Keshishian, H., Farrell, L., et al (2016). Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease. Circulation, 134(4), 270-285. [More Information]
  • Hinson, J., Chopra, A., Lowe, A., Sheng, C., Gupta, R., Kuppusamy, R., O'Sullivan, J., Rowe, G., Wakimoto, H., et al (2016). Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis. Cell Reports, 17(12), 3292-3304. [More Information]
  • O'Sullivan, J., Neylon, A., McGorrian, C., Blake, G. (2016). miRNA-93-5p and other miRNAs as predictors of coronary artery disease and STEMI. International Journal of Cardiology, 224, 310-316. [More Information]
  • Gleeson, B., Martin, K., Ali, M., Kumar, A., Pillai, M., Kumar, S., O'Sullivan, J., Whelan, D., Stocca, A., et al (2015). Bone Marrow-Derived Mesenchymal Stem Cells Have Innate Procoagulant Activity and Cause Microvascular Obstruction Following Intracoronary Delivery: Amelioration by Antithrombin Therapy. Stem Cells, 33(9), 2726-2737. [More Information]
  • Patsch, C., Challet-Meylan, L., Thoma, E., Urich, E., Heckel, T., O'Sullivan, J., Grainger, S., Kapp, F., Sun, L., et al (2015). Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nature Cell Biology, 17(8), 994-1003. [More Information]
  • Roberts, L., Bostrom, P., O'Sullivan, J., Schinzel, R., Lewis, G., Dejam, A., Lee, Y., Palma, M., Calhoun, S., et al (2014). (beta)-Aminoisobutyric acid induces browning of white fat and hepatic (beta)-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metabolism, 19(1), 96-108. [More Information]
  • Turer, A., Lewis, G., O'Sullivan, J., Elmariah, S., Mega, J., Addo, T., Sabatine, M., de Lemos, J., Gerszten, R. (2014). Increases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolism. PloS One, 9(6), e99058. [More Information]
  • O'Sullivan, J., Neylon, A., McGorrian, C., Blake, G. (2014). MicroRNA Expression in Coronary Artery Disease. MicroRNA, 2(3), 205-211.
  • Wang, T., Ngo, D., Psychogios, N., Dejam, A., Larson, M., Vasan, R., Ghorbani, A., O'Sullivan, J., Cheng, S., et al (2013). 2-Aminoadipic acid is a biomarker for diabetes risk. Journal of Clinical Investigation, 123(10), 4309-4317. [More Information]
  • O'Sullivan, J., Leblond, A., O'Dea, J., Hristova, I., Kumar, S., Martin, K., Kumar, A., Caplice, N. (2013). Multidetector computed tomography accurately defines infarct size, but not microvascular obstruction after myocardial infarction. Journal of the American College of Cardiology, 61(2), 208-210. [More Information]
  • Hynes, B., Kumar, A., O'Sullivan, J., Klein Buneker, C., Leblond, A., Weiss, S., Schmeckpeper, J., Martin, K., Caplice, N. (2013). Potent endothelial progenitor cell-conditioned media-related anti-apoptotic, cardiotrophic, and pro-angiogenic effects post-myocardial infarction are mediated by insulin-like growth factor-1. European Heart Journal, 34(10), 782-789. [More Information]
  • Hussaini, A., O'Sullivan, J., Hussain, N., Meany, B. (2012). Association of a bicuspid aortic valve with an abnormally elongated rudimentary chordae tendinae protruding into the left venticular outflow tract. International Journal of Cardiology, 159(3), e45-6. [More Information]
  • Hynes, B., Dollard, J., Murphy, G., O'Sullivan, J., Ruggiero, N., Margey, R., Kiernan, T., McFadden, E. (2011). Enhancing back-up support during difficult coronary stent delivery: single-center case series of experience with the Heartrail II catheter. Journal of Invasive Cardiology, 23(3), E43-E46.
  • O'Sullivan, J., Martin, K., Caplice, N. (2011). Microribonucleic acids for prevention of plaque rupture and in-stent restenosis: "a finger in the dam". Journal of the American College of Cardiology, 57(4), 383-389. [More Information]
  • Martin, K., O'Sullivan, J., Caplice, N. (2011). New therapeutic potential of microRNA treatment to target vulnerable atherosclerotic lesions and plaque rupture. Current Opinion in Cardiology, 26(6), 569-575. [More Information]
  • O'Sullivan, J., Leblond, A., Kelly, G., Kumar, A., Metharom, P., Klein Buneker, C., Alizadeh-Vikali, N., Hristova, I., Hynes, B., O'Connor, R., et al (2011). Potent long-term cardioprotective effects of single low-dose insulin-like growth factor-1 treatment postmyocardial infarction. Circulation: Cardiovascular Interventions, 4(4), 327-335. [More Information]

2017

  • O'Sullivan, J., Morningstar, J., Yang, Q., Zheng, B., Gao, Y., Jeanfavre, S., Scott, J., Fernandez, C., Zheng, H., O'Connor, S., et al (2017). Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. Journal of Clinical Investigation, 127(12), 4394-4402. [More Information]
  • Fusco, D., Pratt, H., Kandilas, S., Cheon, S., Lin, W., Cronkite, D., Basavappa, M., Jeffrey, K., Anselmo, A., O'Sullivan, J., et al (2017). HELZ2 Is an IFN Effector Mediating Suppression of Dengue Virus. Frontiers in Microbiology, 8, 1-20. [More Information]
  • Vernon, S., Coffey, S., Bhindi, R., Hoo, S., Nelson, G., Ward, M., Hansen, P., Asrress, K., Chow, C., Celermajer, D., O'Sullivan, J., Figtree, G. (2017). Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. European Journal of Preventive Cardiology, 24(17), 1824-1830. [More Information]
  • Warren, C., O'Sullivan, J., Friesen, M., Becker, C., Zhang, X., Liu, P., Wakabayashi, Y., Morningstar, J., Shi, X., Choi, J., et al (2017). Induced Pluripotent Stem Cell Differentiation Enables Functional Validation of GWAS Variants in Metabolic Disease. Cell Stem Cell, 20(4), 547-5.57. [More Information]
  • Kimberly, W., O'Sullivan, J., Nath, A., Keyes, M., Shi, X., Larson, M., Yang, Q., Long, M., Vasana, R., Peterson, R., et al (2017). Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis. JCI Insight, 2(9), 1-9. [More Information]

2016

  • Ngo, D., Sinha, S., Shen, D., Kuhn, E., Keyes, M., Shi, X., Benson, M., O'Sullivan, J., Keshishian, H., Farrell, L., et al (2016). Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease. Circulation, 134(4), 270-285. [More Information]
  • Hinson, J., Chopra, A., Lowe, A., Sheng, C., Gupta, R., Kuppusamy, R., O'Sullivan, J., Rowe, G., Wakimoto, H., et al (2016). Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis. Cell Reports, 17(12), 3292-3304. [More Information]
  • O'Sullivan, J., Neylon, A., McGorrian, C., Blake, G. (2016). miRNA-93-5p and other miRNAs as predictors of coronary artery disease and STEMI. International Journal of Cardiology, 224, 310-316. [More Information]

2015

  • Gleeson, B., Martin, K., Ali, M., Kumar, A., Pillai, M., Kumar, S., O'Sullivan, J., Whelan, D., Stocca, A., et al (2015). Bone Marrow-Derived Mesenchymal Stem Cells Have Innate Procoagulant Activity and Cause Microvascular Obstruction Following Intracoronary Delivery: Amelioration by Antithrombin Therapy. Stem Cells, 33(9), 2726-2737. [More Information]
  • Patsch, C., Challet-Meylan, L., Thoma, E., Urich, E., Heckel, T., O'Sullivan, J., Grainger, S., Kapp, F., Sun, L., et al (2015). Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nature Cell Biology, 17(8), 994-1003. [More Information]

2014

  • Roberts, L., Bostrom, P., O'Sullivan, J., Schinzel, R., Lewis, G., Dejam, A., Lee, Y., Palma, M., Calhoun, S., et al (2014). (beta)-Aminoisobutyric acid induces browning of white fat and hepatic (beta)-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metabolism, 19(1), 96-108. [More Information]
  • Turer, A., Lewis, G., O'Sullivan, J., Elmariah, S., Mega, J., Addo, T., Sabatine, M., de Lemos, J., Gerszten, R. (2014). Increases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolism. PloS One, 9(6), e99058. [More Information]
  • O'Sullivan, J., Neylon, A., McGorrian, C., Blake, G. (2014). MicroRNA Expression in Coronary Artery Disease. MicroRNA, 2(3), 205-211.

2013

  • Wang, T., Ngo, D., Psychogios, N., Dejam, A., Larson, M., Vasan, R., Ghorbani, A., O'Sullivan, J., Cheng, S., et al (2013). 2-Aminoadipic acid is a biomarker for diabetes risk. Journal of Clinical Investigation, 123(10), 4309-4317. [More Information]
  • O'Sullivan, J., Leblond, A., O'Dea, J., Hristova, I., Kumar, S., Martin, K., Kumar, A., Caplice, N. (2013). Multidetector computed tomography accurately defines infarct size, but not microvascular obstruction after myocardial infarction. Journal of the American College of Cardiology, 61(2), 208-210. [More Information]
  • Hynes, B., Kumar, A., O'Sullivan, J., Klein Buneker, C., Leblond, A., Weiss, S., Schmeckpeper, J., Martin, K., Caplice, N. (2013). Potent endothelial progenitor cell-conditioned media-related anti-apoptotic, cardiotrophic, and pro-angiogenic effects post-myocardial infarction are mediated by insulin-like growth factor-1. European Heart Journal, 34(10), 782-789. [More Information]

2012

  • Hussaini, A., O'Sullivan, J., Hussain, N., Meany, B. (2012). Association of a bicuspid aortic valve with an abnormally elongated rudimentary chordae tendinae protruding into the left venticular outflow tract. International Journal of Cardiology, 159(3), e45-6. [More Information]

2011

  • Hynes, B., Dollard, J., Murphy, G., O'Sullivan, J., Ruggiero, N., Margey, R., Kiernan, T., McFadden, E. (2011). Enhancing back-up support during difficult coronary stent delivery: single-center case series of experience with the Heartrail II catheter. Journal of Invasive Cardiology, 23(3), E43-E46.
  • O'Sullivan, J., Martin, K., Caplice, N. (2011). Microribonucleic acids for prevention of plaque rupture and in-stent restenosis: "a finger in the dam". Journal of the American College of Cardiology, 57(4), 383-389. [More Information]
  • Martin, K., O'Sullivan, J., Caplice, N. (2011). New therapeutic potential of microRNA treatment to target vulnerable atherosclerotic lesions and plaque rupture. Current Opinion in Cardiology, 26(6), 569-575. [More Information]
  • O'Sullivan, J., Leblond, A., Kelly, G., Kumar, A., Metharom, P., Klein Buneker, C., Alizadeh-Vikali, N., Hristova, I., Hynes, B., O'Connor, R., et al (2011). Potent long-term cardioprotective effects of single low-dose insulin-like growth factor-1 treatment postmyocardial infarction. Circulation: Cardiovascular Interventions, 4(4), 327-335. [More Information]

To update your profile click here. For support on your academic profile contact .